FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Low PCCP Use Could be Missed Opportunity: Study

[ Price : $8.95]

Researchers say manufacturers could make better use of predetermined change control plans for AI-enabled medical devices.

FDA, Federal Prosecutors Take Tougher Stance on Safety Reporting: Analysis

[ Price : $8.95]

A Cooley legal analysis notes that FDA and federal prosecutors are signaling a tougher stance on failures to report patient safety...

CGMP Violations in GC America Inspection

[ Price : $8.95]

FDA warns Alsip, IL-based GC America about CGMP violations in its production of finished drugs.

AstraZeneca Breast Cancer NDA Review Extended by FDA

[ Price : $8.95]

FDA extends its review of an AstraZeneca NDA for camizestrant, an experimental breast cancer therapy, after requesting additional ...

Corcept Plans Resubmission of Cushings NDA

[ Price : $8.95]

Corcept Therapeutics plans to resubmit its NDA for relacorilant as a treatment for patients with Cushings syndrome, following addi...

AbbVies NDA for Dendritic Cell Neoplasms Approved

[ Price : $8.95]

FDA approves an AbbVie NDA for Decnupaz (pivekimab sunirine-pvzy) and its use in treating adults with blastic plasmacytoid dendrit...

FDA-483 Response Can Influence Future Agency Action: Post

[ Price : $8.95]

NSF consultants report on a webinar discussing the best practices in responding to inspection observations in a form FDA-483.

Alchymars ICM SM Inspection Issues

[ Price : $8.95]

FDA warns Indias Alchymars ICM SM Private Limited about CGMP deviations in its production of active pharmaceutical ingredients.

CGMP Issues at Japans Sato Pharmaceutical Co.

[ Price : $8.95]

FDA warns Japans Sato Pharmaceutical Co. about CGMP violations in its production of finished over-the-counter drugs.

U.S. Urges High Court Rejection of Compounding Case

[ Price : $8.95]

The U.S. government urges the Supreme Court to reject an appeal by a Texas compounding pharmacy in a closely watched case over whe...